ERAS in Colorectal Surgery Long-Term Outcomes: What the Evidence Shows
A synthesis of 10 studies examining whether Enhanced Recovery After Surgery protocols translate short-term perioperative gains into durable improvements in survival, oncological outcomes, and healthcare value through 2026.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- ERAS in colorectal surgery long-term outcomes data suggest that high protocol adherence (≥70%) is associated with a 42% reduction in 5-year cancer-specific mortality, based on the largest retrospective cohort (Gustafsson 2016, n = 911).
- Multiple systematic reviews consistently demonstrate short-term benefits — reduced hospital stay by 1.6 to 3 days and lower complication rates — that may serve as a mechanistic bridge to improved long-term outcomes.
- ERAS implementation is associated with improved return to intended oncologic therapy (RIOT), with adherence above the median independently predicting on-time chemotherapy initiation (OR 0.64, 95% CI 0.47–0.88) in a prospective study of 4,529 patients.
- Direct evidence for ERAS improving 5-year overall survival and disease-free survival remains limited and largely retrospective; no large randomised trial has yet confirmed a long-term oncological benefit.
Why This Topic Matters
Colorectal cancer remains among the most common malignancies worldwide, and surgical resection continues to be the primary curative treatment. The perioperative period is a recognised window of vulnerability: surgical stress triggers inflammatory, neuroendocrine, and immunological responses that may influence both immediate recovery and, potentially, long-term oncological trajectory. Enhanced Recovery After Surgery (ERAS) protocols — first formalised for colorectal surgery by Henrik Kehlet and the ERAS Study Group in the early 2000s — were designed to attenuate this stress response through standardised, multimodal perioperative care.
While short-term benefits of ERAS — shorter hospital stays, fewer complications, earlier return of bowel function — are now well established across multiple meta-analyses, the critical question for oncological surgery is whether these early gains translate into durable improvements in survival and cancer control. This evidence review synthesises the growing body of literature examining long-term outcomes following ERAS-managed colorectal surgery, through 2026.
What Evidence Was Reviewed
This synthesis draws on systematic reviews, meta-analyses, retrospective cohorts, and prospective observational studies published between 2016 and 2026 that specifically report long-term outcomes — defined as survival at 3 years or beyond, oncological endpoints, return to intended oncologic therapy (RIOT), or sustained cost-effectiveness — following ERAS-managed colorectal surgery. Studies reporting only short-term perioperative outcomes without follow-up beyond 90 days were excluded from the primary analysis but are referenced where they provide mechanistic context.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| Yang et al. 2026 | SR/MA | 5,876 | CRC, 1–5 yr survival | Pooled survival advantage with ERAS at multiple time points | Moderate |
| Gustafsson et al. 2016 | Retrospective cohort | 911 | CRC, elective, Sweden | ≥70% adherence: HR 0.58 (95% CI 0.39–0.88) for 5-yr cancer-specific death | Moderate |
| Lohsiriwat et al. 2021 | Retrospective cohort | 349 | Stage I–III CRC, Thailand | 5-yr OS 80.3% ERAS vs 65.6% CC; HR 0.54 (95% CI 0.33–0.88) | Moderate |
| Tidadini et al. 2025 | Retrospective cohort | 981 | CRC, France | No significant difference in 5-yr OS or RFS between ERAS and conventional care | Moderate |
| Pang et al. 2021 | Systematic review | 26 studies | Mixed cancer surgery | 4 of 5 studies found ERAS improved RIOT; only 4 of 12 found improved OS | Moderate |
| Pisarska et al. 2019 | Retrospective cohort | 419 | Laparoscopic CRC, Poland | Higher ERAS compliance associated with improved 3-yr survival | Moderate |
| iCral3 (Vignali et al.) 2023 | Prospective multicentre | 4,529 | Colorectal resection, Italy | ERP adherence independently predicted RIOT (OR 0.64, 95% CI 0.47–0.88) | High |
| Kannan et al. 2025 | Systematic review | 1,476 | Colorectal surgery, 11 RCTs | LOS reduction 3–8 days; reduced complications and opioid use | Moderate |
| Sánchez-Guillén et al. 2025 | Cost analysis, ERAS centre | 407 | Elective CRC, Italy | Mean saving €3,677 per patient; postoperative costs down €3,439 | Moderate |
| Crippa et al. 2023 | Retrospective cohort | 105 | Minimally invasive CRC | ERAS reduced surgical stress response and improved cancer-specific survival | Low |
Key Findings: ERAS in Colorectal Surgery Long-Term Outcomes
Short-Term Gains as the Foundation for Long-Term Benefit
The mechanistic rationale for ERAS influencing long-term outcomes rests on a consistent foundation of short-term perioperative improvements. Across multiple systematic reviews encompassing thousands of patients, ERAS protocols have been associated with reductions in hospital stay ranging from 1.6 days (Turaga et al., 18 studies, MD −1.64, 95% CI −2.21 to −1.08) to 3–8 days (Kannan et al., 11 RCTs). Complication rates are consistently lower, with one meta-analysis of 3,421 patients reporting a statistically significant decrease in both overall morbidity and mortality in the ERAS group. These perioperative improvements are hypothesised to reduce the immunosuppressive impact of surgical stress, thereby potentially preserving the body’s ability to mount anti-tumour immune responses during the critical early postoperative period.
Five-Year Survival and Oncological Outcomes
The evidence linking ERAS to improved long-term survival is emerging but not yet definitive. The most frequently cited study — a Swedish retrospective cohort of 911 patients by Gustafsson and colleagues — found that patients achieving 70% or greater adherence to ERAS had a 42% lower risk of 5-year cancer-specific death (HR 0.58, 95% CI 0.39–0.88). A Thai single-centre study similarly reported 5-year overall survival of 80.3% in the ERAS group compared with 65.6% in the conventional care group (HR 0.54, 95% CI 0.33–0.88), with the benefit particularly pronounced in stage III disease.
However, not all studies support this association. A French retrospective cohort of 981 patients by Tidadini and colleagues found no significant difference in 5-year overall survival or recurrence-free survival between ERAS and conventional care. A 2026 preprint meta-analysis by Yang et al. pooling 5,876 patients across 10 studies reported survival advantages at multiple time points, though the included studies were predominantly observational. A systematic review by Pang et al. found that only 4 of 12 studies examining long-term overall survival demonstrated improvement with ERAS, underscoring the inconsistency in the current evidence base.
Return to Intended Oncologic Therapy (RIOT)
One of the most clinically compelling pathways by which ERAS may influence long-term oncological outcomes is through facilitating timely initiation of adjuvant chemotherapy. The iCral3 prospective multicentre study of 4,529 patients across 76 Italian centres found that adherence to the enhanced recovery pathway above the median independently predicted successful RIOT (OR 0.64, 95% CI 0.47–0.88). Surgery performed at an institutional ERAS centre further strengthened this association (OR 0.52, 95% CI 0.40–0.66). The systematic review by Pang et al. reinforced this finding: four of five studies examining RIOT reported improvements in the ERAS group, making this one of the more consistent long-term benefits in the literature.
Elderly patients represent a particularly important subgroup, as they account for a disproportionate share of colorectal cancer diagnoses and face higher perioperative risk. Navarra et al. reported estimated 5-year overall survival of 60.3% (95% CI 49.5–71.1%) and disease-free survival of 86.3% (95% CI 78.1–94.4%) in elderly patients managed with ERAS after elective colorectal cancer surgery. While these figures lack a direct comparison group, they suggest that ERAS-managed elderly patients can achieve survival outcomes broadly comparable to those of younger cohorts in historical series.
The Kannan et al. 2025 systematic review specifically identified elderly patient outcomes as an area requiring further investigation, noting that few RCTs have stratified results by age. The available observational data suggest ERAS is at least safe in older adults and may confer particular benefit given the higher baseline complication rates in this population. However, compliance tends to be lower in older patients, and the relationship between partial compliance and long-term outcomes in the elderly remains poorly characterised.
The long-term survival benefit of ERAS may be most pronounced in patients with locally advanced disease. The Lohsiriwat et al. study from Thailand found that the survival advantage was particularly evident in stage III colorectal cancer, where timely receipt of adjuvant chemotherapy is most critical. In the same study, patients with high ERAS compliance (≥70%) who had stage III disease demonstrated significantly better 5-year overall survival than their conventional care counterparts.
This aligns with the biological rationale: stage III patients are the subgroup most likely to receive and benefit from adjuvant chemotherapy, and ERAS-mediated improvements in postoperative recovery may facilitate earlier and more complete chemotherapy delivery. In contrast, stage I patients (who rarely receive adjuvant treatment) and stage IV patients (whose prognosis is driven largely by metastatic burden) may derive less long-term oncological benefit from perioperative optimisation.
A biological mechanism linking ERAS to improved cancer outcomes has been proposed based on the protocol’s attenuation of the surgical stress response. Crippa et al. (2023) reported that ERAS applied to minimally invasive colorectal cancer surgery reduced markers of surgical stress and was associated with improved long-term cancer-specific survival in a small cohort of 105 patients. The hypothesis is that surgical trauma triggers immunosuppression — mediated by cortisol release, inflammatory cytokine cascades, and impaired natural killer cell function — creating a permissive window for micrometastatic disease progression.
ERAS addresses multiple contributors to this stress response simultaneously: minimising fasting reduces insulin resistance; epidural analgesia and multimodal pain management blunt the neuroendocrine response; early mobilisation and nutrition support accelerate immune recovery. While biologically plausible, the direct causal link between reduced perioperative inflammation and improved long-term cancer control has not been conclusively established in clinical studies.
Sustained cost savings represent an important institutional long-term outcome. A 2025 analysis from an Italian ERAS Qualified Centre (n = 407) found that despite 45% higher preoperative costs — reflecting investment in prehabilitation, nutritional optimisation, and patient education — the ERAS group achieved mean per-patient savings of approximately €3,677 through fewer postoperative complications, shorter hospital stays, and reduced medication and blood transfusion requirements.
The Johns Hopkins financial model estimated that implementation costs of approximately $553,000 were offset by nearly $949,000 in first-year savings, yielding net savings exceeding $395,000. The Alberta provincial ERAS programme similarly demonstrated cost-effectiveness across six implementation sites. These economic data suggest that the value proposition of ERAS extends well beyond the index hospitalisation, particularly when complications that would otherwise require prolonged care or readmission are averted.
Quality and Consistency of Evidence
What the Evidence Does Not Show
No large randomised controlled trial has evaluated ERAS versus conventional care with 5-year survival as a primary endpoint. All current long-term survival data come from retrospective cohorts or observational studies, making it impossible to exclude the influence of confounding factors such as institutional quality, patient selection, and concurrent improvements in surgical technique.
The existing evidence base has several specific limitations. First, ERAS compliance definitions vary substantially across studies — from 43% baseline to 80% thresholds — making cross-study comparisons difficult. Second, most studies are from high-volume academic centres in Northern Europe or East Asia, and generalisability to community hospitals and low-resource settings remains uncertain. Third, the individual contribution of specific ERAS elements to long-term outcomes is unknown; the protocol functions as a bundle, and dismantling studies are lacking.
Additionally, patient-reported outcomes beyond 6–8 weeks are almost entirely absent from the ERAS colorectal literature. The iCral3 study found no effect of ERAS adherence on patient-reported outcome measures at discharge or 6–8 weeks, but longer-term quality of life, functional recovery, and patient satisfaction data are not available. Finally, the interaction between ERAS and specific surgical approaches (robotic, laparoscopic, open) in determining long-term outcomes has not been adequately characterised.
Practical Implications
Based on the current evidence, several considerations emerge for surgical teams managing patients with colorectal cancer within ERAS pathways. These are framed as evidence-based observations rather than directive recommendations.
Multiple studies demonstrate a dose-response relationship between ERAS compliance and outcomes. Achieving ≥70–80% adherence appears to be the threshold at which both short-term and potential long-term benefits become evident. Institutions adopting ERAS may derive greater value from focusing on compliance optimisation rather than merely establishing the protocol.
The most consistent long-term finding is improved return to intended oncologic therapy. For stage III colorectal cancer patients — where adjuvant chemotherapy has established survival benefit — ERAS-mediated faster postoperative recovery may facilitate timely treatment initiation, representing a tangible mechanism for influencing long-term oncological outcomes.
Economic analyses consistently show net savings despite increased preoperative investment. Centres considering ERAS implementation can anticipate positive return on investment within the first year, driven primarily by reduced postoperative complications and shorter hospital stays. This holds in both high-income and resource-constrained environments.
While individual retrospective studies suggest 5-year survival advantages, the inconsistency across studies and the absence of randomised evidence mean that direct survival benefits should not be assumed. Clinicians should frame ERAS as a pathway that optimises perioperative outcomes and facilitates oncological care, rather than as an intervention with proven survival benefit.
Evidence Grade and Bottom Line
Overall Evidence Grade: Moderate
Short-term perioperative benefits of ERAS in colorectal surgery are well established. Evidence for long-term oncological benefit is promising but largely observational and inconsistent across studies. The link between ERAS and improved RIOT is the strongest long-term finding. This evidence grade may change as prospective and randomised long-term data become available.
- ERAS protocols consistently reduce hospital stay, complications, and costs in colorectal surgery — these benefits are robust across multiple meta-analyses.
- High ERAS adherence (≥70%) is associated with improved 5-year cancer-specific survival in retrospective data, but this finding has not been confirmed in randomised trials.
- ERAS facilitates timely return to intended oncologic therapy — the most consistent and clinically actionable long-term finding.
- Direct evidence for disease-free survival and cancer recurrence benefits remains insufficient, with only one of four studies demonstrating improvement.
- All current long-term outcome data are observational, and adequately powered RCTs with survival endpoints are needed before definitive conclusions can be drawn.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Yang K, Liu X, Cui J, et al. Enhanced Recovery After Surgery (ERAS) Increases Long-Term Survival Rate after Surgery in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. medRxiv. 2026. DOI: 10.64898/2026.03.05.26347672
- Gustafsson UO, Oppelstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the ERAS protocol is Associated with 5-Year Survival After Colorectal Cancer Surgery: A Retrospective Cohort Study. World J Surg. 2016;40(7):1741–1747. DOI: 10.1007/s00268-016-3460-y
- Pang Q, Duan L, Jiang Y, Liu H. Oncologic and long-term outcomes of enhanced recovery after surgery in cancer surgeries — a systematic review. World J Surg Oncol. 2021;19:191. DOI: 10.1186/s12957-021-02306-2
- Vignali A, Elmore U, Cossu A, et al. Patient-Reported Outcomes and Return to Intended Oncologic Therapy After Colorectal Enhanced Recovery Pathway: The iCral3 Prospective Study. Ann Surg Open. 2023;4(1):e267. DOI: 10.1097/AS9.0000000000000267
- Lohsiriwat V, Lertbannaphong S, Polakla B, Riansuwan W. Implementation of enhanced recovery after surgery and its increasing compliance improved 5-year overall survival in resectable stage III colorectal cancer. Updates Surg. 2021;73:1143–1150. DOI: 10.1007/s13304-021-01004-8
- Tidadini F, Trilling B, Sage PY, et al. Five-year oncological outcomes after enhanced recovery after surgery (ERAS) compared to conventional care for colorectal cancer: a retrospective cohort of 981 patients. Tech Coloproctol. 2025;29(1):9. DOI: 10.1007/s10151-024-03036-9
- Kannan V, Ullah N, Geddada S, et al. Impact of “Enhanced Recovery After Surgery” (ERAS) protocols vs. traditional perioperative care on patient outcomes after colorectal surgery: a systematic review. Patient Saf Surg. 2025;19:4. DOI: 10.1186/s13037-024-00425-9
- Pisarska M, Torbicz G, Gajewska N, et al. Compliance with the ERAS Protocol and 3-Year Survival After Laparoscopic Surgery for Non-metastatic Colorectal Cancer. World J Surg. 2019;43(10):2552–2560. DOI: 10.1007/s00268-019-05073-0
- Crippa J, Calini G, Santambrogio G, et al. ERAS Protocol Applied to Oncological Colorectal Mini-invasive Surgery Reduces the Surgical Stress Response and Improves Long-term Cancer-specific Survival. Surg Laparosc Endosc Percutan Tech. 2023;33(3):297–301. DOI: 10.1097/SLE.0000000000001181
- Sánchez-Guillén L, Frasson M, García-Granero A, et al. Cost Saving Analysis of an Enhanced Recovery After Surgery (ERAS) Program for Elective Colorectal Surgery in an ERAS Qualified and Training Center. World J Surg. 2025;49(4). DOI: 10.1002/wjs.12174
- Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. World J Surg. 2019;43(3):659–695. DOI: 10.1007/s00268-018-4844-y
- Thanh NX, Chuck AW, Wasylak T, et al. An economic evaluation of the Enhanced Recovery After Surgery (ERAS) multisite implementation program for colorectal surgery in Alberta. Can J Surg. 2016;59(6):415–421. DOI: 10.1503/cjs.006716